Selected article for: "activity broad spectrum and acute respiratory"
Author: McCreary, Erin K; Pogue, Jason M
Title: Coronavirus Disease 2019 Treatment: A Review of Early and Emerging Options
  • Document date: 2020_3_23
    • ID: j0i9ozsz_27
    Snippet: Due to its broad-spectrum antiviral activity, nitazoxanide is being investigated for the management of influenza and other acute respiratory infections. Positive results were demonstrated in a phase 2b/3 study for the outpatient management of influenza, in which a dose of 600 mg by mouth BID of nitazoxanide was associated with a ~1-day improvement in time to resolution of symptoms when compared with placebo (P = .008) [40] . Three phase 3 randomi.....
    Document: Due to its broad-spectrum antiviral activity, nitazoxanide is being investigated for the management of influenza and other acute respiratory infections. Positive results were demonstrated in a phase 2b/3 study for the outpatient management of influenza, in which a dose of 600 mg by mouth BID of nitazoxanide was associated with a ~1-day improvement in time to resolution of symptoms when compared with placebo (P = .008) [40] . Three phase 3 randomized controlled trials in uncomplicated influenza have since been completed (ClinicalTrials. gov Identifier NCT01610245 [March 2018], NCT02612922 [April 2018], and NCT03336619 [September 2019]), although results are unavailable. Nitazoxanide failed to reduce the duration of hospitalization or the time to symptom alleviation in a phase 2 randomized controlled trial in patients with severe acute respiratory illnesses requiring hospitalization, predominantly caused by respiratory viruses [41] . Although the in vitro activity of nitazoxanide against SARS-CoV-2 is encouraging, more data are clearly needed to determine its role in the management of COVID-19.

    Search related documents:
    Co phrase search for related documents
    • acute respiratory infection and antiviral activity: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory infection and broad spectrum: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory infection and broad spectrum antiviral activity: 1
    • acute respiratory infection and control trial: 1, 2, 3, 4, 5, 6
    • acute respiratory infection and hospitalization duration: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22
    • acute respiratory infection and hospitalization require: 1, 2, 3, 4, 5, 6, 7
    • acute respiratory infection and management role: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • acute respiratory infection influenza and hospitalization duration: 1
    • alleviation symptom and antiviral activity: 1
    • alleviation symptom and broad spectrum: 1, 2
    • alleviation symptom and broad spectrum antiviral activity: 1
    • antiviral activity and broad spectrum: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • antiviral activity and broad spectrum antiviral activity: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • antiviral activity and control trial: 1, 2
    • antiviral activity and hospitalization duration: 1, 2, 3
    • antiviral activity and management role: 1, 2, 3, 4
    • antiviral activity and nitazoxanide vitro activity: 1, 2, 3, 4, 5
    • broad spectrum and management role: 1, 2, 3, 4, 5, 6
    • broad spectrum and nitazoxanide vitro activity: 1, 2, 3, 4, 5